529 related articles for article (PubMed ID: 18753411)
1. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
Liu F; Grauer S; Kelley C; Navarra R; Graf R; Zhang G; Atkinson PJ; Popiolek M; Wantuch C; Khawaja X; Smith D; Olsen M; Kouranova E; Lai M; Pruthi F; Pulicicchio C; Day M; Gilbert A; Pausch MH; Brandon NJ; Beyer CE; Comery TA; Logue S; Rosenzweig-Lipson S; Marquis KL
J Pharmacol Exp Ther; 2008 Dec; 327(3):827-39. PubMed ID: 18753411
[TBL] [Abstract][Full Text] [Related]
2. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia.
Schlumberger C; Pietraszek M; Gravius A; Danysz W
Pharmacol Biochem Behav; 2010 Mar; 95(1):23-30. PubMed ID: 19995568
[TBL] [Abstract][Full Text] [Related]
3. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Kinney GG; O'Brien JA; Lemaire W; Burno M; Bickel DJ; Clements MK; Chen TB; Wisnoski DD; Lindsley CW; Tiller PR; Smith S; Jacobson MA; Sur C; Duggan ME; Pettibone DJ; Conn PJ; Williams DL
J Pharmacol Exp Ther; 2005 Apr; 313(1):199-206. PubMed ID: 15608073
[TBL] [Abstract][Full Text] [Related]
4. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain.
O'Brien JA; Lemaire W; Wittmann M; Jacobson MA; Ha SN; Wisnoski DD; Lindsley CW; Schaffhauser HJ; Rowe B; Sur C; Duggan ME; Pettibone DJ; Conn PJ; Williams DL
J Pharmacol Exp Ther; 2004 May; 309(2):568-77. PubMed ID: 14747613
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
Schlumberger C; Pietraszek M; Gravius A; Klein KU; Greco S; Morè L; Danysz W
Eur J Pharmacol; 2009 Nov; 623(1-3):73-83. PubMed ID: 19765575
[TBL] [Abstract][Full Text] [Related]
6. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A; Suzuki G; Maehara S; Hikichi H; Murai T; Murai T; Kawagoe-Takaki H; Hata M; Ito S; Ozaki S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2009 Jul; 330(1):179-90. PubMed ID: 19359526
[TBL] [Abstract][Full Text] [Related]
7. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes.
de Paulis T; Hemstapat K; Chen Y; Zhang Y; Saleh S; Alagille D; Baldwin RM; Tamagnan GD; Conn PJ
J Med Chem; 2006 Jun; 49(11):3332-44. PubMed ID: 16722652
[TBL] [Abstract][Full Text] [Related]
8. Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor.
Bradley SJ; Watson JM; Challiss RA
Mol Pharmacol; 2009 Dec; 76(6):1302-13. PubMed ID: 19737913
[TBL] [Abstract][Full Text] [Related]
9. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Uslaner JM; Parmentier-Batteur S; Flick RB; Surles NO; Lam JS; McNaughton CH; Jacobson MA; Hutson PH
Neuropharmacology; 2009; 57(5-6):531-8. PubMed ID: 19627999
[TBL] [Abstract][Full Text] [Related]
11. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
Chen Y; Goudet C; Pin JP; Conn PJ
Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
[TBL] [Abstract][Full Text] [Related]
12. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator.
Spear N; Gadient RA; Wilkins DE; Do M; Smith JS; Zeller KL; Schroeder P; Zhang M; Arora J; Chhajlani V
Eur J Pharmacol; 2011 Jun; 659(2-3):146-54. PubMed ID: 21335002
[TBL] [Abstract][Full Text] [Related]
13. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
[TBL] [Abstract][Full Text] [Related]
14. Bidirectional variation in glutamate efflux in the medial prefrontal cortex induced by selective positive and negative allosteric mGluR5 modulators.
Isherwood SN; Robbins TW; Dalley JW; Pekcec A
J Neurochem; 2018 Apr; 145(2):111-124. PubMed ID: 29315577
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
Gilmour G; Broad LM; Wafford KA; Britton T; Colvin EM; Fivush A; Gastambide F; Getman B; Heinz BA; McCarthy AP; Prieto L; Shanks E; Smith JW; Taboada L; Edgar DM; Tricklebank MD
Neuropharmacology; 2013 Jan; 64():224-39. PubMed ID: 22884720
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
[TBL] [Abstract][Full Text] [Related]
17. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
[TBL] [Abstract][Full Text] [Related]
18. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
19. Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats.
Nikiforuk A; Popik P; Drescher KU; van Gaalen M; Relo AL; Mezler M; Marek G; Schoemaker H; Gross G; Bespalov A
J Pharmacol Exp Ther; 2010 Dec; 335(3):665-73. PubMed ID: 20739457
[TBL] [Abstract][Full Text] [Related]
20. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Lindemann L; Jaeschke G; Michalon A; Vieira E; Honer M; Spooren W; Porter R; Hartung T; Kolczewski S; Büttelmann B; Flament C; Diener C; Fischer C; Gatti S; Prinssen EP; Parrott N; Hoffmann G; Wettstein JG
J Pharmacol Exp Ther; 2011 Nov; 339(2):474-86. PubMed ID: 21849627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
